Neoleukin Therapeutics (NLTX) News Today $16.60 -1.03 (-5.84%) As of 01/17/2025 Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Head to Head Comparison: Tonix Pharmaceuticals (NASDAQ:TNXP) & Neoleukin Therapeutics (NASDAQ:NLTX)January 17, 2025 | americanbankingnews.comNeoleukin Therapeutics (NASDAQ:NLTX) Shares Down 0.8% Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 0.8%March 14, 2024 | marketbeat.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | benzinga.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 18, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXAugust 1, 2023 | markets.businessinsider.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 28, 2023 | finance.yahoo.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 26, 2023 | benzinga.comBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 24, 2023 | 247wallst.comNeurogene, Neoleukin Announce Planned MergerJuly 19, 2023 | markets.businessinsider.comUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupJuly 18, 2023 | msn.comNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | finanznachrichten.deNeoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological DiseasesJuly 18, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQJuly 18, 2023 | markets.businessinsider.comNeoleukin jumps 7% on Neurogene mergerJuly 18, 2023 | msn.comNeoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTXJuly 18, 2023 | marketwatch.comNLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to ShareholdersJuly 18, 2023 | technews.tmcnet.comNeurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | finance.yahoo.comBiomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)May 23, 2023 | finance.yahoo.comMizuho Securities Reaffirms Their Hold Rating on Neoleukin Therapeutics (NLTX)May 9, 2023 | markets.businessinsider.comNeoleukin Therapeutics promotes general counsel to interim CEOApril 7, 2023 | bizjournals.comNLTX Neoleukin Therapeutics, Inc.March 31, 2023 | seekingalpha.comNeoleukin Therapeutics (NLTX) Receives a Hold from Mizuho SecuritiesMarch 21, 2023 | markets.businessinsider.comHere's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn SituationMarch 10, 2023 | finance.yahoo.comSeattle biotech company CEO steps down amid steep job cutsMarch 10, 2023 | bizjournals.comNeoleukin Therapeutics Shares Climb 29% on 70% Workforce Reduction, Strategic AlternativesMarch 9, 2023 | marketwatch.comShares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or mergerMarch 9, 2023 | msn.comNeoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 MonthsMarch 9, 2023 | finance.yahoo.comNeoleukin Therapeutics to cut 70% workforce, CEO steps downMarch 9, 2023 | msn.comNeoleukin Therapeutics Eyes Strategic Alternatives, Will Cut StaffMarch 8, 2023 | marketwatch.comMizuho Securities Keeps Their Hold Rating on Neoleukin Therapeutics (NLTX)March 8, 2023 | markets.businessinsider.comNeoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionMarch 8, 2023 | finance.yahoo.comNeoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual MeetingDecember 12, 2022 | finance.yahoo.comNeoleukin (NLTX) Stops Development of Lead Drug, Stock DownNovember 16, 2022 | finance.yahoo.comMizuho Securities downgrades Neoleukin Therapeutics (NLTX) to a HoldNovember 15, 2022 | markets.businessinsider.comNeoleukin Pauses Development Of NL-201, Cuts 40% Of Employee StrengthNovember 15, 2022 | finance.yahoo.comNeoleukin cut to Hold at Stifel on plans to drop lead assetNovember 15, 2022 | seekingalpha.com5 Analysts Have This to Say About Neoleukin TherapeuticsNovember 15, 2022 | markets.businessinsider.comNeoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate UpdateNovember 15, 2022 | finance.yahoo.comTrading was temporarily halted for "NLTX" at 04:11 PM with a stated reason of "News pending."November 14, 2022 | marketbeat.comNeoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual MeetingNovember 3, 2022 | finance.yahoo.comWe're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn RateOctober 1, 2022 | finance.yahoo.comNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call TranscriptAugust 10, 2022 | seekingalpha.comNeoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call PresentationAugust 10, 2022 | seekingalpha.com Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address NLTX Media Mentions By Week NLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NLTX News Sentiment▼0.000.49▲Average Medical News Sentiment NLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NLTX Articles This Week▼10▲NLTX Articles Average Week Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunome News Ginkgo Bioworks News LENZ Therapeutics News Arbutus Biopharma News Tectonic Therapeutic News Cullinan Therapeutics News Dianthus Therapeutics News Autolus Therapeutics News CARGO Therapeutics News Kura Oncology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NLTX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLTX Stock Alerts